Heartflow Builds Evidence Base Across the Heart Disease Care Continuum, From Precision Risk Stratification to CT-Guided Intervention Planning

Core Insights - Heartflow, Inc. is advancing its AI technology for coronary artery disease (CAD) management, presenting new clinical evidence and launching the NAVIGATE-PCI Registry to enhance patient care and outcomes [1][3][10] Group 1: Clinical Evidence and Registry Launch - Heartflow presented new clinical evidence at the American College of Cardiology (ACC) Annual Scientific Session, establishing Heartflow Plaque Analysis as a leading tool for early identification of high-risk CAD patients [1][4] - The NAVIGATE-PCI Registry has enrolled its first patient, marking a significant effort to evaluate the real-world impact of AI-driven insights on clinical strategy and procedural efficiency in PCI planning [2][10] Group 2: Heartflow Plaque Analysis - Heartflow Plaque Analysis is highlighted for its long-term validation in risk stratification and its effectiveness in lipid management, reinforcing its role as a personalized and cost-effective solution for CAD [4][5] - A study tracking over 15,000 patients demonstrated that extensive plaque volume is a strong predictor of major adverse cardiovascular events (MACE), with patients facing a fourfold higher risk [5][6] Group 3: Comparative Effectiveness and Economic Impact - An analysis involving nearly 3,800 patients showed that management guided by Heartflow's Plaque Analysis led to a higher initiation of lipid-lowering therapy and achievement of LDL goals compared to traditional methods [7] - A budget impact analysis indicated that Heartflow's Plaque Analysis achieves cost-effectiveness within two years, with total population savings of $140 million, emphasizing the economic sustainability of the technology [8] Group 4: Future Directions and Technology Integration - The NAVIGATE-PCI Registry aims to generate evidence on how pre-procedural insights can influence clinical decisions and enhance PCI procedures, improving efficiency and outcomes for patients [10][12] - Heartflow's technology is positioned to redefine precision cardiovascular care, with over 1,400 institutions adopting its solutions globally, supported by extensive clinical validation [16][17]